Patent EP0059948A1 successfully refreshed from Google Patents.
EP0059948A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel aroylimidazolones
Assignee: Gruppo Lepetit SpA
•
Filing: 1982-03-04
•
Granted: —
•
Expires: 2002-03-04
Abstract
Abstract This invention relates to aroylimidazole-2-ones and their acid and base addition salts as well as their use as cardiotonics in the treatment of cardiac failure.
Inventors
- 👤 Richard C. Dage
- 👤 Richard A. Schnettler
- 👤 Frank P. Palopoli
- 👤 J. Martin Grisar
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-06 09:32
CPC Classifications
C; C07; C07D; C07D233/00; C07D233/54; C07D233/66; C07D233/84; C07D233/70
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
95 words
A compound of the formula wherein Q and T are each an oxygen atom or a divalent sulfur atom; R is hydrogen, lower alkyl, lower alkanoyl or benzoyl; R 1 is hydrogen or lower alkyl; Ar is optionally substituted pyridyl, pyrryl, thienyl, furanyl or optionally substituted phenyl; and the pharmaceutically acceptable acid base addition salts thereof with the proviso that when Q and T are both oxygen atoms then Ar cannot be thienyl, furanyl, or optionally substituted phenyl and with the additional proviso that when R 1 is methyl then Ar cannot be unsubstituted 3-pyridyl.
Claim 2
Dependent Claim
95 words
A compound of the formula wherein Q and T are each an oxygen atom or a divalent sulfur atom; R is hydrogen, lower alkyl, lower alkanoyl or benzoyl; R 1 is hydrogen or lower alkyl; Ar is optionally substituted pyridyl, pyrryl, thienyl, furanyl or optionally substituted phenyl; and the pharmaceutically acceptable acid base addition salts thereof with the proviso that when Q and T are both oxygen atoms then Ar cannot be thienyl, furanyl, or optionally substituted phenyl and with the additional proviso that when R 1 is methyl then Ar cannot be unsubstituted 3-pyridyl.
Claim 3
Dependent Claim
18 words
A compound of claim 1 wherein R is hydrogen and Q and T are each an oxygen atom.
Claim 4
Dependent Claim
20 words
A compound of claim 2 wherein Ar is 2- or 4-pyridyl optionally substituted with lower alkyl, halogen or lower alkoxy.
Claim 5
Dependent Claim
13 words
A compound of claim 3 wherein R 4 is hydrogen, methyl or ethyl.
Claim 6
Dependent Claim
18 words
A compound of claim 2 wherein Ar is 4-pyridyl optionally substituted with lower alkyl, halogen or lower alkoxy.
Claim 7
Dependent Claim
13 words
A compound of claim 5 wherein R 1 is hydrogen, methyl or ethyl.
Claim 8
Dependent Claim
10 words
A compound of claim 6 wherein Ar is unsubstituted 4-pyridyl.
Claim 9
Dependent Claim
21 words
A compound of claim 1 wherein Ar is unsubstituted 4-pyridyl, R is hydrogen and R 1 is hydrogen, that is, 1,3-dihydro-4-isonicotinoyl-2H-imidazole-2-one.
Claim 10
Dependent Claim
21 words
A compound of claim 1 wherein Ar is unsubstituted 4-pyridyl, R is hydrogen and R 1 is methyl, that is, 1,3-dihydro-4-isonicotinoyl-5-methyl-2H-imidazole-2-one.
Claim 11
Dependent Claim
21 words
A compound of claim 1 wherein Ar is unsubstituted 4-pyridyl, R is hydrogen and R 1 is ethyl, that is 1,3-dihydro-4-ethyl-5-isonicotinoyl-2H-imidazole-2-one.
Claim 12
Dependent Claim
23 words
Pharmaceutical composition for the treatment of cardiac failure, comprising a compound according to claims 1 to 10 and usual carriers, adjuvants or additives.
Claim 13
Dependent Claim
19 words
Use of the compounds according to claims 1 to 10 for preparing a pharmaceutical composition according to claim 11.
References Cited (Backward Citations)
GB1305273A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.